| Vol. 11.43 – 13 November, 2020 |
| |
|
|
| The authors identified the metalloproteinase inhibitor TIMP1 as a molecular switch that determines the effects of senescence in prostate cancer. Senescence driven either by PTEN deficiency or chemotherapy limited the progression of prostate cancer in mice. [Cancer Cell] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists suggested that low androgen levels correlate with luminal plasticity in prostate development and may have implications for understanding how AR inhibition promotes lineage plasticity in prostate cancer. [Stem Cell Reports] |
|
|
|
| Investigators report that DEP-domain containing mTOR-interacting protein (DEPTOR) is a downstream target of the tumor suppressor, p53, whose activity was positively correlated with DEPTOR expression both in vitro in cell cultures and in vivo in mouse tissues. [Cell Death & Disease] |
|
|
|
| Researchers showed that platelet-derived programmed cell death protein-1 (PD-L1) regulated the growth of PD-L1 negative tumors and that interference with platelet binding to PD-L1 negative cancer cells promoted T cell-induced cancer cytotoxicity. [Scientific Reports] |
|
|
|
| The authors found STAT3 inhibitors from natural sources and found that Xanthium fruit extracts decreased phosphorylation of STAT3‐Y705. 8‐Epi‐xanthatin (EXT) was isolated from the extracts. When DU145 prostate cancer cells were treated with EXT, p‐STAT3‐Y705 was decreased with an IC50 of 3.2μM. [Phytotherapy Research] |
|
|
|
| Researchers reported the phenolic and flavonoid constituents, antioxidant activity, and potential of the L. usitatissimum plant extract against prostate cancer cells. The phenolic and flavonoid compound profile of the extract were established using HPLC analysis. [AMB Express] |
|
|
|
| To acquire a training set for deep-learning, scientists imaged eight standard cancer cell lines. These cell lines were derived from colorectal and prostate carcinoma, prostate and mammary adenocarcinoma, osteosarcoma, as well as neutrophilic, monocytic and T-cell leukemia. [Communications Biology] |
|
|
|
|
| The maturing mutational landscape of cancer genomes, the development and application of clinical interventions and evolving insights into tumour-associated functions reveal unexpected features of the protein kinase C (PKC) family of serine/threonine protein kinases. [Nature Reviews Cancer] |
|
|
|
| XPO1 is overexpressed in patients with cancer, including in those with pancreatic, gastric, prostate and colorectal cancers, and such overexpression is associated with disease progression, treatment resistance, and inferior overall survival or progression-free survival. [Nature Reviews Clinical Oncology] |
|
|
|
| Preclinical knowledge of dysregulated pathways and potential biomarkers for urological cancers has undergone limited translation into the clinic. Moreover, the low approval rate of new anticancer drugs and the heterogeneous drug responses in patients indicate that current preclinical models do not always reflect the complexity of malignant disease. [Nature Reviews Urology] |
|
|
|
|
| WindMIL Therapeutics have demonstrated the therapeutic promise for MILs® as a potential cancer immunotherapy for a wide range of solid tumor indications. In the study, bone marrow and blood samples were collected from patients with non-small cell lung cancer, prostate cancer, squamous cell carcinoma of the head and neck, glioblastoma and breast cancer. [WindMIL Therapeutics (GlobeNewswire, Inc.)] |
|
|
|
|
| April 11 – April 13, 2021 San Diego, California, United States |
|
|
|
|
|
| The University of British Columbia (UBC) – Vancouver, British Columbia, Canada |
|
|
|
| Stanford University – Stanford, California, United States |
|
|
|
| Pfizer – La Jolla, California, United States |
|
|
|
| Lerner Research Institute – Cleveland, Ohio, United States |
|
|
|
| IRCCS Candiolo Cancer Institute – Candiolo, Italy |
|
|
|
|